Impact of Coronary Artery Disease and Percutaneous Coronary Intervention on Transcatheter Aortic Valve Implantation
Journal of Interventional Cardiology · 24.03.2021 · 2021 · 1-7
DOI: 10.1155/2021/6672400 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Interventional Cardiology, erschienen am 24.03.2021. Verfasst von Anthony G Matta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Rangueil University Hospital, Toulouse, France. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The prevalence of coronary artery disease (CAD) detected in preoperative work-up for transcatheter aortic valve implantation (TAVI) is high. Instead, the management of a concomitant CAD remains unclear. We evaluate the impact of CAD and percutaneous coronary intervention (PCI) on TAVI procedures. Materials and Methods. A retrospective study was conducted on 1336 consecutive patients who underwent TAVI in Toulouse University Hospital, Rangueil, France. The studied population was divided into 2 groups: CAD-TAVI group and No CAD-TAVI group. Then, the CAD-TAVI group was segregated into 2 subgroups: PCI-TAVI group and No PCI-TAVI group. In-hospital adverse clinical outcomes were assessed in each group.
Results
Pre-TAVI work-up revealed significant CAD in 36% of 1030 patients eligible for inclusion in the study. The overall prevalence of in-hospital death, stroke, major or life-threatening bleeding, minor bleeding, major vascular complications, minor vascular complications, pacemaker implantation, and acute kidney injury was 2.7%, 2.4%, 2.8%, 3.6%, 3.9%, 7.5%, 12.5%, and 2.7%, respectively. Among the studied population, 55% were admitted to the cardiac care unit. No significant statistical difference was observed between groups.
Discussion
CAD-TAVI population was not more likely to develop in-hospital adverse clinical outcomes post-TAVI procedure compared to others. Also, no significant difference regarding in-hospital death was observed. In parallel, performing PCI prior to TAVI did not increase the risk of in-hospital death and complications. The difference in terms of the distribution of antithrombotic regimen may explain the higher prevalence of bleeding events in the PCI-TAVI group.
Conclusion
This study provides direct clinical relevance useful in daily practice. No negative impact has been attributed to the presence of a concomitant CAD and/or preoperative PCI on the TAVI hospitalization period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Rangueil University Hospital, Toulouse, France.
- Faculty of Medicine, Holy Spirit University of Kaslik, Jounieh, Lebanon.
ORCID-Profile: Anthony G Matta
Zitieren
APA
Matta, A. G., Lhermusier, T., Parada, F. C., Bouisset, F., Canitrot, R., Nader, V., Blanco, S., Elbaz, M., Roncalli, J., & Carrié, D. (2021). Impact of Coronary Artery Disease and Percutaneous Coronary Intervention on Transcatheter Aortic Valve Implantation. Journal of Interventional Cardiology, 2021, 1-7. https://doi.org/10.1155/2021/6672400
Vancouver
Matta AG, Lhermusier T, Parada FC, Bouisset F, Canitrot R, Nader V, et al. Impact of Coronary Artery Disease and Percutaneous Coronary Intervention on Transcatheter Aortic Valve Implantation. Journal of Interventional Cardiology. 2021;2021:1-7. doi:10.1155/2021/6672400
BibTeX
@article{Matta2021,
author = {Matta, Anthony G and Lhermusier, Thibault and Parada, Francisco Campelo and Bouisset, Frederic and Canitrot, Ronan and Nader, Vanessa and Blanco, Stéphanie and Elbaz, Meyer and Roncalli, Jerome and Carrié, Didier},
title = {Impact of Coronary Artery Disease and Percutaneous Coronary Intervention on Transcatheter Aortic Valve Implantation},
journal = {Journal of Interventional Cardiology},
year = {2021},
volume = {2021},
pages = {1--7},
doi = {10.1155/2021/6672400}
}
EUVIMED